HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Viking Therapeutics, maintaining a price target of $90. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.
October 24, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Viking Therapeutics, maintaining a price target of $90. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.
The reiteration of a Buy rating and maintenance of a $90 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100